Iterum Therapeutics plc: net intangible assets excluding goodwill
Net intangible assets excluding goodwill for Iterum Therapeutics plc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Iterum Therapeutics plc financial histories
What this measure means
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
Exact concept: us-gaap:IntangibleAssetsNetExcludingGoodwill. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-12-31 to 2024-12-31. The SEC response was captured on 2026-09-21.
Reading these values
This selected numerical history matches Net finite-lived intangible assets for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2024-12-31 | 19,746,000 | USD | 2025-02-07 | 10-K · 0000950170-25-015857 |
| At date | 2022-12-31 | 1,719,000 | USD | 2024-03-28 | 10-K · 0000950170-24-037615 |
| At date | 2021-12-31 | 3,435,000 | USD | 2023-03-16 | 10-K · 0000950170-23-008300 |
Related financial histories
- Iterum Therapeutics plc: total assets
- Iterum Therapeutics plc: total liabilities
- Iterum Therapeutics plc: stockholders equity
- Iterum Therapeutics plc: cash and cash equivalents
- Iterum Therapeutics plc: net income or loss
- Iterum Therapeutics plc: operating cash flow
- Iterum Therapeutics plc: capital expenditure payments
- Iterum Therapeutics plc: contract revenue excluding tax
- Iterum Therapeutics plc: financing cash flow
- Iterum Therapeutics plc: investing cash flow
- Iterum Therapeutics plc: retained earnings or deficit
- Iterum Therapeutics plc: basic weighted-average shares
- Iterum Therapeutics plc: diluted weighted-average shares
- Iterum Therapeutics plc: basic earnings per share
- Iterum Therapeutics plc: diluted earnings per share
- Iterum Therapeutics plc: income tax expense or benefit
- Iterum Therapeutics plc: net property, plant and equipment
- Iterum Therapeutics plc: share-based compensation expense
- Iterum Therapeutics plc: operating income or loss
- Iterum Therapeutics plc: current assets
- Iterum Therapeutics plc: current liabilities
- Iterum Therapeutics plc: current accounts payable
- Iterum Therapeutics plc: net finite-lived intangible assets
- Iterum Therapeutics plc: operating expenses
- Iterum Therapeutics plc: research and development expense
- Iterum Therapeutics plc: accumulated other comprehensive income or loss
- Iterum Therapeutics plc: operating lease right-of-use asset
- Iterum Therapeutics plc: operating lease liability
- Iterum Therapeutics plc: long-term debt
- Iterum Therapeutics plc: gross property, plant and equipment
- Iterum Therapeutics plc: accumulated depreciation on property, plant and equipment
- Iterum Therapeutics plc: other noncurrent assets
- Iterum Therapeutics plc: other noncurrent liabilities
- Iterum Therapeutics plc: accrued current liabilities
- Iterum Therapeutics plc: prepaid expenses and other current assets
- Iterum Therapeutics plc: pre-tax income or loss from continuing operations
- Iterum Therapeutics plc: profit or loss including noncontrolling interests
- Iterum Therapeutics plc: comprehensive income or loss
- Iterum Therapeutics plc: net income available to common stockholders
- Iterum Therapeutics plc: general and administrative expense
- Iterum Therapeutics plc: depreciation expense
- Iterum Therapeutics plc: amortization of intangible assets
- Iterum Therapeutics plc: nonoperating interest expense
- Iterum Therapeutics plc: other nonoperating income or expense
- Iterum Therapeutics plc: nonoperating income or expense
- Iterum Therapeutics plc: current income tax expense or benefit
- Iterum Therapeutics plc: interest paid, net
- Iterum Therapeutics plc: income taxes paid, net
- Iterum Therapeutics plc: proceeds from issuing common stock
- Iterum Therapeutics plc: operating lease payments
- Iterum Therapeutics plc: change in accounts payable
Inspect the source
- Entity
- Iterum Therapeutics plc / CIK 0001659323
- Captured
- 2026-09-21T17:22:13.659Z
- SEC response SHA-256
c1f8397ebc2e5bacf7539c921cd573e3e0a05a5b75a0010f26037e6da7255340
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001659323.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))